OMER
Omeros Corporation · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | +1 | 30.11K | $575,627 | +1 | −1 |
| Q2 2026 | 74 | -1 | 26.77M | $254.67M | +8 | −10 |
| Q1 2026 | 78 | +7 | 23.56M | $249.21M | +9 | −2 |
| Q4 2025 | 71 | -2 | 30.19M | $466.97M | n/a | −2 |
| Q3 2025 | 17 | 0 | 17.59M | $72.13M | n/a | n/a |
| Q2 2025 | 14 | +1 | 14.04M | $42.12M | +1 | n/a |
| Q1 2025 | 10 | +1 | 6.15M | $50.54M | +1 | n/a |
| Q4 2024 | 9 | 0 | 4.83M | $47.77M | +1 | −1 |
| Q3 2024 | 8 | +1 | 3.34M | $13.26M | +1 | n/a |
| Q2 2024 | 7 | n/a | 3.21M | $13.02M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | D. E. Shaw & Co. ✦ | 1.58M | n/a | $6.40M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Geode Capital Management ✦ (passive) | 1.33M | n/a | $5.41M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Two Sigma Investments ✦ | 159.45K | n/a | $647,351 | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 61.58K | n/a | $250,003 | 0.0% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 35.18K | n/a | $143,000 | 0.0% | n/c | 1 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 25.80K | n/a | $104,748 | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 7 | Millennium Management ✦ | 16.97K | n/a | $68,910 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 4.17M shares, $8.90M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 10.00K sh · $209,500
Officer · 10.00K sh · $209,500
Officer · 25.00K sh · $463,540
Officer · 25.00K sh · $466,128
Director · 5.00K sh · $94,381
Director · 5.00K sh · $95,080
Director · 5.00K sh · $92,632
Officer · 906 sh · $17,305
Officer · 10.00K sh · $189,500
Director · 15.00K sh · $276,772
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology